Navigation Links
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
Date:12/8/2008

US Oncology Affiliated Physicians Participate in ASH Conference

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network will present findings from a randomized, multicenter Phase III trial that compared FCR and PCR in patients with B-cell chronic lymphocytic leukemia (CLL).

The study results will be given in an oral presentation by Dr. Craig Reynolds of Ocala Oncology Center at the 50th Annual Meeting of the American Society of Hematology (ASH) held December 6-9, 2008 in San Francisco. Dr. Reynolds is the lead investigator and serves as co-chairman, and chairman for new protocol development, of US Oncology's National Lung Cancer Research Committee.

Purine analog-based regimens have emerged as highly active regimens in the treatment of chronic lymphocytic lymphoma (CLL). Promising results have been reported with the combination of fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) by Keating and colleagues at the University of Texas M.D. Anderson Cancer Center. Previous US Oncology Research Network, as well as a Mayo Clinic and MSKCC trials, evaluated the combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR); results suggested similar efficacy with less infectious complications than that seen with FCR.

The current multicenter, randomized, community-based trial was conducted to compare FCR and PCR in previously untreated or minimally treated B-cell chronic lymphocytic leukemia. The primary end point of the study was infectious complications with efficacy and safety as secondary endpoints. Correlative studies of immune function were conducted by Kay and colleagues at the Mayo Clinic and will be reported separately.

"This study establishes the role of these regimens in the treatment of CCL," said Dr. Reynolds. "New therapies such as these offer hope for our
'/>"/>

SOURCE US Oncology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
2. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
3. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
5. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
6. Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
7. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
8. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
9. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
10. Gene Therapy Corrects Sickle Cell Disease in Laboratory Study
11. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 ... defines and segments the concerned market with analysis ... at $261.8 million in 2014, and is estimated ... CAGR of 19.3% from 2014 to 2019. ... Mannequin-Based Simulation Market for an analysis of industry ...
(Date:6/2/2015)... -- Intarcia Therapeutics, Inc. today announced the ... announced synthetic royalty / equity convert financing, bringing the ... Convertible Limited Recourse Notes from Intarcia and are entitled ... future global net sales of ITCA 650 until the ... the option, commencing upon U.S. regulatory approval of ITCA ...
(Date:6/2/2015)... 2015 ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... from the U.S. Food and Drug Administration (FDA) of ... Oral Solution 5mg/5mL. Trailing twelve-month sales for the product ... competitors. ANI expects to begin shipping to its customers ... and CEO of ANI Pharmaceuticals, stated, "This ANDA represents ...
Breaking Medicine Technology:North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 3
... YORK, Sept. 15 Otherwise known as ED, ... to obtain or maintain an erection for satisfactory sexual ... the United States and occurs most frequently in men ... heart disease, vascular disease and neurological diseases. However, according ...
... Broadspire, a Crawford Company (NYSE: CRDA ; ... services provider, is proud to announce that Gary Anderberg, Ph.D., ... winner of Risk & Insurance magazine,s 2010 Risk ... as a leader with Broadspire,s e-Triage system, which helps analyze ...
Cached Medicine Technology:Men's Sexual Health and Medical Talk Show Expert Dr. Ridwan Shabsigh, MD Talks About How Erectile Dysfunction Affects Quality of Life 2Men's Sexual Health and Medical Talk Show Expert Dr. Ridwan Shabsigh, MD Talks About How Erectile Dysfunction Affects Quality of Life 3Broadspire's Gary Anderberg Named Risk Innovator of the Year 2Broadspire's Gary Anderberg Named Risk Innovator of the Year 3
(Date:6/2/2015)... 2015 Aidan Booth And Steve ... public yesterday, and has since received rave reviews ... reviewer Tiffany Hendricks has weighed in with her ... course on her website HonestyFirstReviews.com. , "These days ... marketers looking to hone their business skills has ...
(Date:6/2/2015)... 2015 On Wednesday, May 27, 2015, professional ... a top speed of 207.9 mph. In the process, ... break the 200 mph mark. Jay Leno was on ... episode of Jay Leno’s Garage, which will air on CNBC ... 8.5 mile high speed oval at the Continental Tire Proving ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 UCLA Health ... of intent to partner and expand urgent care services ... to approval by the University of California Board of ... transaction will allow UCLA Health to purchase a minority ... Beverly Hills, Calabasas, Newbury Park and Northridge and creates ...
(Date:6/2/2015)... King of Prussia, PA (PRWEB) June 02, 2015 ... Business Process Outsourcing solutions for health plans in the ... announces their participation as a sponsor and exhibitor at ... trade group, America’s Health Insurance Plans. The conference will ... TMG Health exhibition booth, #1303, will offer opportunities for ...
(Date:6/2/2015)... On October 1, 2015 the transition to ICD-10 ... , On Monday, June 1st Congressman Kevin Brady, ... and Means Committee, and 12 members of the Committee ... Services, urging the administration to provide a smooth transition ... is the newest coding system for healthcare professionals to ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4
... even when athletes mistakenly thought they were taking growth ... -- When athletes think they are taking a performance-enhancing ... if they never really take the drug. , So ... received human growth hormone supplements while the other half ...
... US primary care physicians,Novartis earns the highest sales ... Sanofi-Aventis, according to new,research from TNS Healthcare. Novartis ... consistent ability to build strong physician relationships.,Though Pfizer ... has,greater variability in Europe, while Merck,s European performance ...
... ROSWELL, Ga., June 17 Kimberly-Clark Professional is,donating ... Columbus, Ind.,businesses and residents clean up from the ... know that Columbus was hit very hard by ... Barfoot, Vice President of,Kimberly-Clark Professional, North America. "At ...
... June 17 ,Shire Limited (LSE: SHP, Nasdaq: SHPGY), ... of data from a,randomized, long-term safety and tolerability ... (mesalamine). The primary endpoints,of this study were to ... UC patients over 12 months. Data were published ...
... more readily than a commonly used colorectal cancer drug ... but with fewer side effects, MIT researchers have found. ... anticancer agent, but the newly investigated compound, known as ... body tissues from damage. , "This compound, the antitumor ...
... extremely rare condition. There is no definitive treatment for ... intervention, especially endoscopic treatment has recently been used and ... Dr. TH Kim and his colleagues from the Gyeongsang ... the World Journal of Gastroenterology. , Blunt abdominal trauma, ...
Cached Medicine News:Health News:Sports Doping's Effect May Be in the Mind 2Health News:Sports Doping's Effect May Be in the Mind 3Health News:Sports Doping's Effect May Be in the Mind 4Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 2Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 3Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 5Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 6Health News:MIT researchers see alternative to common colorectal cancer drug 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: